Six Ways For PD-1 Lung Cancer Programs To Differentiate

The PD-1 and PD-L1 inhibitors have delivered stellar data in a number of tumor types and hold mega-blockbuster promise – but with so many in the class, sponsors are looking to stand out. Pull-out table provides side-by-side comparison of leading programs.

More from Clinical Trials

More from R&D